Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer

NCT04529850 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer
Oral Mucositis

Interventions

DRUG: Drug: GC4419
RADIATION: Intensity-modulated radiation therapy (IMRT)
DRUG: Cisplatin

Sponsor

Galera Therapeutics, Inc.